Fasoracetam: what does this study show?
30 adolescents aged 12–17. One placebo week preceded four weeks of symptom-guided dosing up to 400 mg twice daily; single-dose pharmacokinetics examined 50–800 mg.
Clinical severity and improvement scores improved. Adverse-event incidence did not differ between the placebo week and active-treatment weeks.
Small, genetically selected sample with an open-label/single-blind sequential design. It is not a parallel randomized efficacy trial or evidence for healthy adults.
These findings apply to the population and methods described above.
What might this mean, and what would change the interpretation?
Small, genetically selected sample with an open-label/single-blind sequential design. It is not a parallel randomized efficacy trial or evidence for healthy adults.
What would clarify this: Independent replication with clinically meaningful outcomes and longer safety follow-up.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.